IP Library › Granted Patent US 12,246,022
Granted Patent B2
US 12,246,022 · App. 18/470,182 · Granted Mar 11, 2025

Compositions and methods for treating, preventing or reversing age associated inflammation and disorders

Inventors: John M. Sedivy (Barrington, RI); Marco De Cecco (Pawtucket, RI)
Assignee: BROWN UNIVERSITY
A61K31/52A61K31/513A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,246,022
App. No.
18/470,182
Granted
Mar 11, 2025
Kind
B2
Abstract

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).

Claims (20)

1. A method for slowing down the progression of and/or lessening the symptoms of Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorder, dementia with Lewy Bodies, frontotemporal dementia, mild cognitive impairment, Parkinson's disease, progressive supra nuclear palsy, Rett Syndrome, or Aicardi-Goutieres syndrome in a patient in need thereof, the method comprising administering a therapeutically effective amount of censavudine to the patient.

2. The method of claim 1 comprising administering about 1 μg/kg to about 100 mg/kg of censavudine to the patient per day.

3. The method of claim 2 comprising administering about 1 mg/kg to about 50 mg/kg of censavudine to the patient per day.

4. The method of claim 3 comprising administering about 5 mg/kg of censavudine to the patient per day.

5. The method of claim 3 comprising administering about 10 mg/kg of censavudine to the patient per day.

6. The method of claim 3 comprising administering about 15 mg/kg of censavudine to the patient per day.

7. The method of claim 3 comprising administering about 20 mg/kg of censavudine to the patient per day.

8. The method of claim 1 comprising administering 1 mg to 500 mg of censavudine to the patient once a day, twice a day, or three times a day.

9. The method of claim 8 comprising administering 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, or 150 mg of censavudine to the patient once a day, twice a day, or three times a day.

10. The method of claim 1 , wherein the censavudine is orally administered to the patient in the form of a tablet, capsule, or suspension.

11. The method of claim 1 slowing down the progression of and/or lessening the symptoms of Alzheimer's disease.

12. The method of claim 1 slowing down the progression of and/or lessening the symptoms of amyotrophic lateral sclerosis.

13. The method of claim 1 slowing down the progression of and/or lessening the symptoms of autism spectrum disorder.

14. The method of claim 1 slowing down the progression of and/or lessening the symptoms of dementia with Lewy Bodies.

15. The method of claim 1 for curing, slowing down the progression of and/or lessening the symptoms of frontotemporal dementia.

16. The method of claim 1 slowing down the progression of and/or lessening the symptoms of mild cognitive impairment.

17. The method of claim 1 slowing down the progression of and/or lessening the symptoms of Parkinson's disease.

18. The method of claim 1 slowing down the progression of and/or lessening the symptoms of progressive supra nuclear palsy.

19. The method of claim 1 slowing down the progression of and/or lessening the symptoms of Rett Syndrome.

20. The method of claim 1 slowing down the progression of and/or lessening the symptoms of Aicardi-Goutieres syndrome.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: SEDIVY, JOHN M.; DE CECCO, MARCO
To: BROWN UNIVERSITY
Reel/Frame 066478/0167 →
Continuity (5)
Continuation 16934826 · Jul 21, 2020
Continuation In Part PCTUS2020015043 · Jan 24, 2020
Provisional Application 62907251 · Sep 27, 2019
Provisional Application 62797109 · Jan 25, 2019
Related Publication 20240197745A1 · Jun 20, 2024
References Cited (341)
US 4172896A · Uno et al. · 1979 [cited by applicant]
US 5358970A · Ruff et al. · 1994 [cited by applicant]
US 5427798A · Ludwig et al. · 1995 [cited by applicant]
US 5541231A · Ruff et al. · 1996 [cited by applicant]
US 5731000A · Ruff et al. · 1998 [cited by applicant]
US 5763493A · Ruff et al. · 1998 [cited by applicant]
US 6110973A · Young · 2000 [cited by applicant]
US 6291670B1 · Ohrui et al. · 2001 [cited by applicant]
US 6333315B1 · Ohrui et al. · 2001 [cited by applicant]
US 6403568B1 · Ohrui et al. · 2002 [cited by applicant]
US 7339053B2 · Kohgo et al. · 2008 [cited by applicant]
US 7589078B2 · Cheng et al. · 2009 [cited by applicant]
US 7625877B2 · Kohgo et al. · 2009 [cited by applicant]
US 8173623B2 · Crawford et al. · 2012 [cited by applicant]
US 8193165B2 · Cheng et al. · 2012 [cited by applicant]
US 8334295B2 · Guo et al. · 2012 [cited by applicant]
US 8354421B2 · He et al. · 2013 [cited by applicant]
US 8431745B2 · Crawford et al. · 2013 [cited by applicant]
US 8445669B2 · Sato et al. · 2013 [cited by applicant]
US 8513205B2 · Anderson et al. · 2013 [cited by applicant]
US 9051288B2 · Nagai et al. · 2015 [cited by applicant]
US 9126971B2 · Cheng et al. · 2015 [cited by applicant]
US 9212174B2 · Iriyama et al. · 2015 [cited by applicant]
US 9221832B2 · Hilpert et al. · 2015 [cited by applicant]
US 9249171B2 · Ortiz et al. · 2016 [cited by applicant]
US 9422605B2 · Dubnau et al. · 2016 [cited by applicant]
US 9441223B2 · Dubnau et al. · 2016 [cited by applicant]
US 9777035B2 · Girijavallabhan et al. · 2017 [cited by applicant]
US 9822138B2 · Vachal et al. · 2017 [cited by applicant]
US 9993547B2 · Stenler et al. · 2018 [cited by applicant]
US 10059940B2 · Zhong et al. · 2018 [cited by applicant]
US 10071985B2 · Graupe et al. · 2018 [cited by applicant]
US 10100307B2 · Prochiantz et al. · 2018 [cited by applicant]
US 10258575B2 · Li · 2019 [cited by applicant]
US 10266558B2 · Ivachtchenko et al. · 2019 [cited by applicant]
US 10363220B2 · Li · 2019 [cited by applicant]
US 10449208B2 · Da Costa et al. · 2019 [cited by applicant]
US 10450335B2 · Fu et al. · 2019 [cited by applicant]
US 10479801B2 · Graham et al. · 2019 [cited by applicant]
US 10519159B2 · Paparin et al. · 2019 [cited by applicant]
US 10537589B2 · Hazuda et al. · 2020 [cited by applicant]
US 10654827B2 · Graupe et al. · 2020 [cited by applicant]
US 11793814B2 · Sedivy et al. · 2023 [cited by applicant]
US 20030003468A1 · Crow · 2003 [cited by applicant]
US 20040229262A1 · Franco et al. · 2004 [cited by applicant]
US 20050113324A1 · Bondarev et al. · 2005 [cited by applicant]
US 20060020042A1 · McDONALD et al. · 2006 [cited by applicant]
US 20060160087A1 · Mcgrath et al. · 2006 [cited by applicant]
US 20100048726A1 · McDONALD et al. · 2010 [cited by applicant]
US 20110150997A1 · Shah et al. · 2011 [cited by applicant]
US 20140113952A1 · Dubnau et al. · 2014 [cited by applicant]
US 20150018297A1 · Jo et al. · 2015 [cited by applicant]
US 20150038446A1 · Ambati et al. · 2015 [cited by applicant]
US 20150104511A1 · Malhotra et al. · 2015 [cited by applicant]
US 20160130260A1 · Ortiz et al. · 2016 [cited by applicant]
US 20160339019A1 · Laberge et al. · 2016 [cited by applicant]
US 20170224680A2 · Laberge et al. · 2017 [cited by applicant]
US 20170335320A1 · Prochiantz et al. · 2017 [cited by applicant]
US 20180002366A1 · Girijavallabhan et al. · 2018 [cited by applicant]
US 20180050000A1 · Mckearn et al. · 2018 [cited by applicant]
US 20180065999A1 · Vachal et al. · 2018 [cited by applicant]
US 20180153859A1 · Didsbury et al. · 2018 [cited by applicant]
US 20180185372A1 · Schinazi et al. · 2018 [cited by applicant]
US 20180230464A1 · Zhong · 2018 [cited by applicant]
US 20180305688A1 · Zhong · 2018 [cited by applicant]
US 20180362562A1 · Raheem et al. · 2018 [cited by applicant]
US 20190022115A1 · Girijavallabhan et al. · 2019 [cited by applicant]
US 20190038659A1 · Nath et al. · 2019 [cited by applicant]
US 20190055273A1 · Beigelman et al. · 2019 [cited by applicant]
US 20190083478A1 · Houston et al. · 2019 [cited by applicant]
US 20190084963A1 · Shi · 2019 [cited by applicant]
US 20190177326A1 · Alexandre et al. · 2019 [cited by applicant]
US 20190183912A1 · Da Costa et al. · 2019 [cited by applicant]
US 20190185508A1 · Alexandre et al. · 2019 [cited by applicant]
US 20190262365A1 · Paparin et al. · 2019 [cited by applicant]
US 20190315769A1 · Graham et al. · 2019 [cited by applicant]
US 20190321380A1 · De et al. · 2019 [cited by applicant]
US 20190388336A1 · Barrett et al. · 2019 [cited by applicant]
US 20190388590A1 · Barrett et al. · 2019 [cited by applicant]
US 20200010834A1 · Novick et al. · 2020 [cited by applicant]
US 20200010868A1 · Duan et al. · 2020 [cited by applicant]
US 20200038389A1 · Bauer et al. · 2020 [cited by applicant]
US 20200101098A1 · Hazuda et al. · 2020 [cited by applicant]
US 20200138845A1 · Scott · 2020 [cited by applicant]
US 20200171020A1 · Balan et al. · 2020 [cited by applicant]
WO WO2000069876A1 · 2000 [cited by applicant]
WO WO2008054808A2 · 2008 [cited by applicant]
WO WO2009153009A1 · 2009 [cited by applicant]
WO WO2012068636A1 · 2012 [cited by applicant]
WO WO2013057469A1 · 2013 [cited by applicant]
WO WO2014184553A1 · 2014 [cited by applicant]
WO WO2016005327A1 · 2016 [cited by applicant]
WO WO2016138425A1 · 2016 [cited by applicant]
WO WO2016149561A1 · 2016 [cited by applicant]
WO WO2017050803A1 · 2017 [cited by applicant]
WO WO2017138022A1 · 2017 [cited by applicant]
WO WO2018102358A1 · 2018 [cited by applicant]
WO WO2018136920A1 · 2018 [cited by applicant]
WO WO2018191093A1 · 2018 [cited by applicant]
WO WO2018203235A1 · 2018 [cited by applicant]
WO WO2019009793A1 · 2019 [cited by applicant]
WO WO2019133712A1 · 2019 [cited by applicant]
WO WO2019140365A1 · 2019 [cited by applicant]
WO WO2019171285A1 · 2019 [cited by applicant]
WO WO2019246422A1 · 2019 [cited by applicant]
WO WO2020007070A1 · 2020 [cited by applicant]
WO WO2020014041A1 · 2020 [cited by applicant]
WO WO2020018352A1 · 2020 [cited by applicant]
WO WO2020018399A1 · 2020 [cited by applicant]
WO WO2020031131A1 · 2020 [cited by applicant]
WO WO2020044257A1 · 2020 [cited by applicant]
WO WO2020053811A1 · 2020 [cited by applicant]
WO WO2020058844A1 · 2020 [cited by applicant]
WO WO2020081622A1 · 2020 [cited by applicant]
WO WO2020092621A1 · 2020 [cited by applicant]
WO WO2020128525A1 · 2020 [cited by applicant]
WO WO2020131649A1 · 2020 [cited by applicant]
WO WO2020185676A1 · 2020 [cited by applicant]
WO WO2021041317A1 · 2021 [cited by applicant]
Alexandrova, E., et al., “Sense Transcripts Originated From an Internal Part of the Human Retrotransposon LINE-1 5' UTR,” Gene 15(1): 46-53, Elsevier, Netherlands (Dec. 2012). [cited by applicant]
An, W., et al., “Characterization of a Synthetic Human LINE-1 Retrotransposon ORFeus-Hs,” Mobile DNA 2, BioMed Central Ltd., London (Feb. 2011). [cited by applicant]
Athanikar, J., et al., “A YY1-Binding Site Is Required for Accurate Human Line-1 Transcription Initiation,” Nucleic Acids Research 32(13): 3846-3855, Oxford University Press, London (Jul. 2004). [cited by applicant]
Baker, D.J., et al., “Clearance of P16ink4a-positive Senescent Cells Delays Ageing-associated Disorders,” Nature 479(7372):232-236, Nature Publishing Group, United Kingdom (Nov. 2011). [cited by applicant]
Baker, D.J., et al., “Naturally Occurring P16(Ink4a)-positive Cells Shorten Healthy Lifespan,” Nature 530(7589):184-189, Nature Publishing Group, United Kingdom (Feb. 2016). [cited by applicant]
Benjamini, Y. and Hochberg, Y., “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society. Series B (Methodological) 57(1):289-300, Wiley, Un… [cited by applicant]
Bingham, A.L., et al., “Over One Hundred Solvates of Sulfathiazole,” Chemical Communications 7:603-604, Royal Society of Chemistry, United States (2001). [cited by applicant]
Bowen, L. N., et al., “HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy,” Neurology 87(17):1756-1762, American Academy of Neurology, United States (published online Sep. 2016… [cited by applicant]
Brown, J. P., et al., “Bypass of Senescence After Disruption of P21cipl/wafl Gene in Normal Diploid Human Fibroblasts,” Science 277(5327): 831-834, American Association for the Advancement of Science, United States (Aug… [cited by applicant]
Brydon, E., “Cshl neuroscientists show 'jumping genes' may contribute to aging-related brain defects,” 7 pages, Cold Spring Harbor Laboratory, United States (Apr. 2013). [cited by applicant]
Bundo, M., et al., “Increased L1 Retrotransposition in the Neuronal Genome in Schizophrenia,” Neuron 81(2):306-313, Cell Press, United States (Jan. 2014). [cited by applicant]
Bussian, T.J., et al., “Clearance of Senescent Glial Cells Prevents Tau-dependent Pathology and Cognitive Decline,” Nature 562(7728):578-582, Nature Publishing Group, United Kingdom (Oct. 2018). [cited by applicant]
Caira, M.R., et al., “Preparation and Crystal Characterization of a Polymorph, a Monohydrate, and an Ethyl Acetate Solvate of the Antifungal Fluconazole,” Journal of Pharmaceutical Sciences 93(3):601-611, American Pharm… [cited by applicant]
Chang, J., et al., “Clearance of Senescent Cells by ABT263 Rejuvenates Aged Hematopoietic Stem Cells in Mice,” Nature Medicine 22:78-83, Nature Research, United States (Jan. 2016). [cited by applicant]
Childs, B G., et al., “Cellular Senescence in Aging and Age-related Disease: From Mechanisms to Therapy,” Nature Medicine 21(12):1424-1435, Nature Publishing Company, United States (Dec. 2015). [cited by applicant]
Childs, B G., et al., “Senescent Intimal Foam Cells Are Deleterious at All Stages of Atherosclerosis,” Science 354(6311):472-477, American Association for the Advancement of Science, United States (Oct. 2016). [cited by applicant]
Chinta, S., et al., “Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson's Disease,” Cell Reports 22(4):930-940, Cell Press, United States (Jan. … [cited by applicant]
Chu, S. C., et al., “Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity,” Journal of Natural Products 55(2):179-183, American Chemical Society, United States (Feb. 1992). [cited by applicant]
Chung, H.Y., et al., “Molecular inflammation: underpinnings of aging and age-related diseases,” Ageing Research Reviews 8(1):18-30, Elsevier Science, United Kingdom (Jan. 2009). [cited by applicant]
Coppe, J.P., et al., “The Senescence-associated Secretory Phenotype: the Dark Side of Tumor Suppression,” Annual Review of Pathology 5:99-118, Annual Reviews, United States (2010). [cited by applicant]
Coufal, N. G., et al., “L1 Retrotransposition in Human Neural Progenitor Cells,” Nature 460(7259):1127-1131, Nature Publishing Group, United Kingdom (Aug. 2009). [cited by applicant]
Criscione, S.W., et al., “Transcriptional Landscape of Repetitive Elements in Normal and Cancer Human Cells,” BMC Genomics 15:583, BioMed Central, United Kingdom (Jul. 2014). [cited by applicant]
Dai, L., et al., “Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition,” BMC Biochem 12:18, 11 pages, BioMed Central Ltd., United Kingdom (May 20… [cited by applicant]
De Cecco, M., et al., “Genomes of replicatively senescent cells undergo global epigenetic changes leading to gene silencing and activation of transposable elements,” Aging Cell 12(2):247-256, Wiley-Blackwell Publishing … [cited by applicant]
De Cecco, M., et al., “Transposable elements become active and mobile in the genomes of aging mammalian somatic tissues,” Aging 5(12):867-883, Impact Journals LLC, United States (Dec. 2013). [cited by applicant]
De Koning, A.P.J., et al., “Repetitive Elements May Comprise Over Two-thirds of the Human Genome,” PLos Genetics 7(12):e1002384, Public Library of Science, United States (Dec. 2011). [cited by applicant]
Demaria, M., et al., “An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA,” Developmental Cell 31(6): 722-733, Cell Press, United States (Dec. 2014). [cited by applicant]
Demaria, M., et al., “Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse,” Cancer Discovery 7(2):165-176, American Association for Cancer Research, United States (Feb. 2017). [cited by applicant]
Denli, A.M., et al., “Primate-specific ORF0 Contributes to Retrotransposon-mediated Diversity,” Cell 163(3):583-593, Cell Press, United States (Oct. 2015). [cited by applicant]
Dhanwani, R., et al., “Cytosolic Sensing of Immuno-stimulatory DNA, the Enemy Within,” Current Opinion in Immunology 50:82-87, Elsevier, United Kingdom (Feb. 2018). [cited by applicant]
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, pp. 602-614, American Psychiatric Association Publishing, Washington, DC (2013). [cited by applicant]
Dou, Z., et al., “Cytoplasmic Chromatin Triggers Inflammation in Senescence and Cancer,” Nature 550(7676):402-406, Nature Publishing Group, United Kingdom (Oct. 2017). [cited by applicant]
Else, J., et al., “Pharmacokinetics of Lamivudine and Lamivudine-triphosphate After Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study,” Antimicrobial Age… [cited by applicant]
Engel, P., “These Staggering Maps Show How Much The World's Population Is Aging,” Business Insider (May 2014). [cited by applicant]
Erwin, J.A., et al., “Mobile DNA Elements in the Generation of Diversity and Complexity in the Brain,” Nature Reviews. Neuroscience 15(8):497-506, Nature Publishing Group, United Kingdom (Aug. 2014). [cited by applicant]
Farr, J.N., et al., “Targeting Cellular Senescence Prevents Age-related Bone Loss in Mice,” Nature Medicine 23(9):1072-1079, Nature Publishing Company, United States (Sep. 2017). [cited by applicant]
Fikes, B. J., “HIV drugs may help Alzheimer's, says study proposing an undiscovered root cause,” MedicalXpress.com, 5 pages, The San Diego Union-Tribune, United States (Nov. 2018). [cited by applicant]
Fowler, B. J., et al., “Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity,” Science 346(6212):1000-1003, American Association for the Advancement of Science, United States (Nov. 20… [cited by applicant]
Franceschi, C. and Campisi, J., “Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-associated Diseases,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 69 Suppl 1… [cited by applicant]
Frasca, D. and Blomberg, B., “Inflammaging Decreases Adaptive and Innate Immune Responses in Mice and Humans,” Biogerontology 17(1):7-19, Kluwer Academic, Netherlands (Feb. 2016). [cited by applicant]
Fumagalli, M., et al., “Stable Cellular Senescence Is Associated With Persistent DDR Activation,” PloS One 9(10):e110969, Public Library of Science, United States (Oct. 2014). [cited by applicant]
Gautier, G., et al., “A Type I Interferon Autocrine-paracrine Loop Is Involved in Toll-like Receptor-induced Interleukin-12p70 Secretion by Dendritic Cells,” The Journal of Experimental Medicine 201(9):1435-1446, Rockef… [cited by applicant]
Giri Repbase., 31 pages, accessed at [URL:http://www.girinst.org/repbase/update/browse.php] on Apr. 22, 2021. [cited by applicant]
Gorbunova, V., et al., “Human Genomics. Sleeping dogs of the genome,” Science 346(6214):1187-1188, American Association for the Advancement of Science, United States (Dec. 2014). [cited by applicant]
Hampel, H., et al., “Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein,” Brain Research Bulletin 61(3):243-253, Elsevier Inc., U… [cited by applicant]
Han, J. S., “Non-long terminal repeat (non-LTR) retrotransposons: mechanisms, recent developments, and unanswered questions,” Mobile DNA 1(1):15, 12 pages, BioMed Central Ltd., United Kingdom (May 2010). [cited by applicant]
Hancks, D.C. and Kazazian, H.H., Jr., “Active Human Retrotransposons: Variation and Disease,” Current Opinion in Genetics & Development 22(3):191-203, Elsevier, United Kingdom (Jun. 2012). [cited by applicant]
Herbig, U., et al., “Cellular Senescence in Aging Primates,” Science 311(5765):1257, American Association for the Advancement of Science, United States (Mar. 2006). [cited by applicant]
Herbig, U., et al., “Telomere Shortening Triggers Senescence of Human Cells Through a Pathway Involving Atm, P53, and P21(Cip1), but Not P16(Ink4a),” Molecular Cell 14(4):501-513, Cell Press, United States (May 2004). [cited by applicant]
Huang, C.R.L., et al., “Active Transposition in Genomes,” Annual Review of Genetics 46:651-475, Annual Reviews, United States (2012). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/015043, Commissioner for Patents, Virginia, mailed on Jul. 7, 2020. [cited by applicant]
Ishak, C.A., et al., “An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences,” Molecular Cell 64(6):1074-1087, Cell Press, United States (Dec. 2016). [cited by applicant]
Itahana, K., et al., “Methods to Detect Biomarkers of Cellular Senescence: the Senescence-associated Beta-galactosidase Assay,” Methods in Molecular Biology 371:21-31, Humana Press, United States (2007). [cited by applicant]
Ivanov, A., et al., “Lysosome-mediated Processing of Chromatin in Senescence,” The Journal of Cell Biology 202(1):129-143, Rockefeller University Press, United States (Jul. 2013). [cited by applicant]
Jurk, D., et al., “Chronic Inflammation Induces Telomere Dysfunction and Accelerates Ageing in Mice,” Nature Communications 2:4172, Nature Pub. Group, United Kingdom (Jun. 2014). [cited by applicant]
Kamentsky, L., et al., “Improved Structure, Function and Compatibility for CellProfiler: Modular High-Throughput Image Analysis Software,” Bioinformatics 27(8):1179-1180, Oxford University Press, United Kingdom (Apr. 20… [cited by applicant]
Katoh, K. and Standley, D.M., “MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability,” Molecular Biology and Evolution 30(4):772-780, Oxford University Press, United States (Apr… [cited by applicant]
Kent, J., “UCSC In-Silico PCR,” Dec. 2013, 1 page, accessed on [URL:https://genome.ucsc.edu/cgi-bin/hgPcr]. [cited by applicant]
Kim, D., et al., “HISAT: A Fast Spliced Aligner With Low Memory Requirements,” Nature Methods 12(4):357-360, Nature Pub. Group, United States (Apr. 2015). [cited by applicant]
Kreiling, J.A., et al., “Age-associated Increase in Heterochromatic Marks in Murine and Primate Tissues,” Aging Cell 10(2):292-304, Wiley-Blackwell, United Kingdom (Apr. 2011). [cited by applicant]
Kreiling, J.A., et al., “Contribution of Retrotransposable Elements to Aging,” In book: Human Retrotransposons in Health and Disease, pp. 297-321, Springer, Cham (Jan. 2017). [cited by applicant]
Langmead, B., “Aligning Short Sequencing Reads With Bowtie,” Current Protocols in Bioinformatics Chapter 11:Unit 11.7, John Wiley & Sons, United States (Dec. 2010). [cited by applicant]
Le, O.N.L., et al., “Ionizing Radiation-induced Long-term Expression of Senescence Markers in Mice Is Independent of P53 and Immune Status,” Aging Cell 9(3):398-409, Wiley-Blackwell, United Kingdom (Jun. 2010). [cited by applicant]
Lee, M-H., and Chun, J., “Mosaic APP Gene Recombination in Alzheimer's Disease-What's Next?,” Journal of Experimental Neuroscience 13: 1179069519849669, Rockefeller University Press, United States (May 2019). [cited by applicant]
Lee, M-H., et al., “Somatic APP gene recombination in Alzheimer's disease and normal neurons,” Nature 563(7733):639-645, Nature Publishing Group, United Kingdom (Nov. 2018). [cited by applicant]
Cognitive Vitality Reports, “LINE1 inhibition (with nucleoside reverse transcriptase inhibitors),” Alzheimer's Drug Discovery Foundation, Jul. 31, 2020. [cited by applicant]
Levin, J., Conference Report, “Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days,” 9th IAS Conference on HIV Science; Paris, France; Jul. 23- 26, 2017, accessed at [https://ww… [cited by applicant]
Li, Q., et al., “FOXA1 Mediates P16(INK4a) Activation During Cellular Senescence,” The EMBO Journal 32(6):858-873, Wiley Blackwell, United Kingdom (Mar. 2013). [cited by applicant]
Li, W. et al., “The EMBL-EBI Bioinformatics Web and Programmatic Tools Framework,” Nucleic Acids Research 43:W580-W584, Oxford University Press, United Kingdom (Jul. 2015). [cited by applicant]
Liao, Y., et al., “FeatureCounts: An Efficient General Purpose Program for Assigning Sequence Reads to Genomic Features,” Bioinformatics 30(7):923-930, Oxford University Press, Oxford (Apr. 2014). [cited by applicant]
Lopez-Otin, C., et al., “The Hallmarks of Aging,” Cell 153(6):1194-1217, Cell Press, United States (Jun. 2013). [cited by applicant]
Martinez-Santibanez, G., et al., “Imaging White Adipose Tissue With Confocal Microscopy,” Methods in Enzymology 537:17-30, Academic Press, United States (2014). [cited by applicant]
Mattson, M.P., “Perspective: Does Brown Fat Protect Against Diseases of Aging?,” Ageing Research Reviews 9(1):69-76, Elsevier Science, United Kingdom (Jan. 2010). [cited by applicant]
Meter, M.V., et al., “SIRT6 Represses LINE1 Retrotransposons by Ribosylating KAP1 but This Repression Fails With Stress and Age,” Nature Communications 5:5011, Nature Pub. Group, United Kingdom (Sep. 2014). [cited by applicant]
Michaud, K., et al., “Pharmacologic Inhibition of Cyclin-dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts,” Cancer Research 70(8):3228-3238, American Association for Cancer… [cited by applicant]
Moles, J-P., et al., “Cytosolic RNA:DNA Duplexes Generated by Endogenous Reverse Transcriptase Activity as Autonomous Inducers of Skin Inflammation in Psoriasis,” PLoS One 12(1):e0169879, Public Library of Science, Unit… [cited by applicant]
Montoya-Durango, D.E., et al., “Epigenetic Control of Mammalian Line-1 Retrotransposon by Retinoblastoma Proteins,” Mutation Research 665(1-2):20-28, Elsevier, Netherlands (Jun. 2009). [cited by applicant]
Zhang, X., et al., “New Understanding of the Relevant Role of LINE-1 Retrotransposition in Human Disease and Immune Modulation,” Frontiers in Cell and Developmental Biology, 8:657, doi:10.3389/fcell.2020.00657 (Aug. 202… [cited by applicant]
NCT01767701, “Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE),” first posted online Jan. 14, 2013, accessed at https://clinicaltrials.gov/ct2/show/NCT01767701, accessed on May 20, 2021, 8 p… [cited by applicant]
NCT02363452, “Reverse Transcriptase Inhibitors in AGS (RTIs in AGS),” first posted online Feb. 16, 2015, accessed at https://clinicaltrials.gov/ct2/show/NCT02363452, accessed on May 20, 2021, 9 pages. [cited by applicant]
NCT02437110, “Herv-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS),” first posted online May 7, 2015, accessed at https://clinicaltrials.gov/ct2/show/NCT02437110, access… [cited by applicant]
Olovnikov, I.A., et al., “Key Role of the Internal Region of the 5′-UTR Segment in the Transcription Acitivity of the Human L1 Retrotransposon,” Molecular Biology 41(3):453-458, Pleiades Publishing, Inc. (May-Jun. 2007). [cited by applicant]
Pawelec, G., et al., “Inflammation, Ageing and Chronic Disease,” Current Opinion in Immunology 29:23-28, Elsevier, United Kingdom (Aug. 2014). [cited by applicant]
Penzkofer, T., et al., “L1Base: From Functional Annotation to Prediction of Active Line-1 Elements,” Nucleic Acids Research 33(Database Issue): D498-D500, Information Retrieval ltd., United Kingdom (Jan. 2005). [cited by applicant]
Rangwala, S.H., et al., “Many LINE1 Elements Contribute to the Transcriptome of Human Somatic Cells,” Genome Biology 10: R100, BioMed Central, United Kingdom (2009). [cited by applicant]
Reich, M., et al., “GenePattern 2.0,” Nature Genetics 38(5):500-501, Nature Publishing Group, United States (May 2006). [cited by applicant]
Robinson, M.D., et al., “edgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data,” Bioinformatics 26(1):139-140, Oxford University Press, United Kingdom (Jan. 2010). [cited by applicant]
Rodic, N., et al., “Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers,” The American Journal of Pathology 184(5):1280-1286, Elsevier, United States (May 2014). [cited by applicant]
Safrin, S., “Antiviral Agents (Chapter 49). In: Basic and Clinical Pharmacology,” 14 [cited by applicant]
Salama, R., et al., “Cellular Senescence and Its Effector Programs,” Genes & Development 28(2):99-114, Cold Spring Harbor Laboratory Press, United States (Jan. 2014). [cited by applicant]
Saleh, A., et al., “Transposable Elements, Inflammation, and Neurological Disease,” Frontiers in Neurology 10: 894, Frontiers Research Foundation, Switzerland (Aug. 2019). [cited by applicant]
Sanjana, N.E., et al., “Improved Vectors and Genome-wide Libraries for CRISPR Screening,” Nature Methods 11(8):783-784, Nature Pub. Group, United States (Aug. 2014). [cited by applicant]
Schafer, M.J., et al., “Cellular Senescence Mediates Fibrotic Pulmonary Disease,” Nature Communications 8:14532, Nature Pub. Group, United Kingdom (Feb. 2017). [cited by applicant]
Schoenmaker, M., et al., “Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study,” European Journal of Human Genetics: EJHG 14(1):79-84, Nature Publishing Group, Unit… [cited by applicant]
Schorl, C. and Sedivy, J.M., “Analysis of Cell Cycle Phases and Progression in Cultured Mammalian Cells,” Methods 41(2):143-150, Academic Press, United States (Feb. 2007). [cited by applicant]
Sedivy, J. M., et al., “Death by transposition—the enemy within?” Bioessays 35(12):1035-1043, John Wiley and Sons Inc., United States (published online Oct. 2013, published in print Dec. 2013). [cited by applicant]
Shalem, O., et al., “Genome-Scale CRISPR-Cas9 Knockout Screening In Human Cells,” Science, 343(6166):84-87, American Association for the Advancement of Science, United States (Jan. 2014). [cited by applicant]
Simon, M., et al., “Inhibition of retrotransposition improves health and extends lifespan of SIRT6 knockout mice,” BioRXiv.org, accessed at URL:[https://www.biorxiv.org/content/10.1101/460808v1.full], 53 pages, Cold Spr… [cited by applicant]
Singh, T. and Newman, A.B., “Inflammatory Markers in Population Studies of Aging,” Ageing Research Reviews 10(3):319-329, Elsevier Science, United Kingdom (Jul. 2011). [cited by applicant]
Skowron, G., and Ogden, R., eds., “Reverse transcriptase inhibitors in HIV/AIDS Therapy,” pp. 1-527, Humana Press Inc., United States (2006). [cited by applicant]
Sonnier, L., et al., “Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1,” The Journal of Neuroscience 27(5):1063-1071, Society for Neuroscience, United States (Ja… [cited by applicant]
Stetson, D.B., et al., “Trex1 Prevents Cell-intrinsic Initiation of Autoimmunity,” Cell 134(4):587-598, Cell Press, United States (Aug. 2008). [cited by applicant]
Stoddart, C.A., et al., “Oral Administration of the Nucleoside EFdA (4′-Ethyny1-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice an… [cited by applicant]
Suarez, N.A., et al., “LINE-1 Retrotransposons in Healthy and Diseased Human Brain,” Developmental Neurobiology 78(5): 434-455, Wiley Subscription Services, United States (May 2018). [cited by applicant]
Subramanian, A., et al., “Gene Set Enrichment Analysis: a Knowledge-based Approach for Interpreting Genome-wide Expression Profiles,” Proceedings of the National Academy of Sciences 102(43):15545-15550, The National Aca… [cited by applicant]
Sun, X., et al., “Transcription Factor Profiling Reveals Molecular Choreography and Key Regulators of Human Retrotransposon Expression,” Proceedings of the National Academy of Sciences of the United States of America 11… [cited by applicant]
Takahashi, A., et al., “Downregulation of Cytoplasmic Dnases Is Implicated in Cytoplasmic DNA Accumulation and SASP in Senescent Cells,” Nature Communications 9:1249, Nature Research, United Kingdom (Mar. 2018). [cited by applicant]
Tam, O. H., et al., “Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia,” Cell Reports 29(5):1164-1177, Cell Press, United States (Oct… [cited by applicant]
Tchkonia, T., et al., “Fat Tissue, Aging, and Cellular Senescence,” Aging Cell 9(5): 667-684, Wiley-Blackwell, United Kingdom (Oct. 2010). [cited by applicant]
Thomas, C.A., et al., “Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation,” Cell Stem Cell 21(3):319-331, Cell Press, United States (Sep. 20… [cited by applicant]
Toti, L., et al., “Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis,” American Journal of Physiology-Gastrointest… [cited by applicant]
University of Texas Health Science Center at San Antonio, “First-in-human trial of senolytic drugs encouraging: Small pilot study points to feasibility of larger trials in age-related diseases,” ScienceDaily.com, access… [cited by applicant]
Van Tonder, E.C., et al., “Preparation and Physicochemical Characterization of 5 Niclosamide Solvates and 1 Hemisolvate,” AAPS PharmSciTech 5(1):E12, American Association of Pharmaceutical Scientists, United States (Feb… [cited by applicant]
Volkman, H.E. and Stetson D.B., “The Enemy Within: Endogenous Retroelements and Autoimmune Disease,” Nature Immunology 15(5): 415-422, Nature America Inc., United States (May 2014). [cited by applicant]
Waaijer, M.E., et al., “The Number of p16INK4a Positive Cells in Human Skin Reflects Biological Age,” Aging Cell 11(4):722-725, Wiley-Blackwell, United Kingdom (Aug. 2012). [cited by applicant]
Waterhouse, A.M., et al., “ Jalview Version 2—A Multiple Sequence Alignment Editor and Analysis Workbench,” Bioinformatics 25(9):1189-1191, Oxford University Press, United Kingdom (May 2009). [cited by applicant]
West, A.P., et al., “Mitochondrial DNA in Innate Immune Responses and Inflammatory Pathology,” Nature Reviews. Immunology 17(6):363-375, Nature Pub. Group, United Kingdom (Jun. 2017). [cited by applicant]
West, A.P., et al., “Mitochondrial DNA Stress Primes the Antiviral Innate Immune Response,” Nature 520:553-557, Nature Publishing Group, United Kingdom (Apr. 2015). [cited by applicant]
Westarp, M. E., et al., “Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis,” NeuroReport 4(6):819-822, Rapid Communications of Oxford Ltd., United Kingdom (Jun. 1993). [cited by applicant]
Wikipedia., “Senotherapy,” 5 pages, accessed at [URL:https://en.wikipedia.org/wiki/Senotherapy] on Apr. 23, 2021. [cited by applicant]
Xie, Y., et al., “Characterization of L1 Retrotransposition With High-throughput Dual-luciferase Assays,” Nucleic Acids Research 39(3):e16, Oxford University Press, United Kingdom (Feb. 2011). [cited by applicant]
Xu, M., et al., “Senolytics Improve Physical Function and Increase Lifespan in Old Age,” Nature Medicine 24(8): 1246-1256, Nature Publishing Company, United States (Aug. 2018). [cited by applicant]
Ye, J., et al., “Primer-BLAST: a Tool to Design Target-specific Primers for Polymerase Chain Reaction,” BMC Bioinformatics 13:134 (Jun. 2012). [cited by applicant]
Zhao, B., et al., “Somatic LINE-1 Retrotransposition in Cortical Neurons and Non-brain Tissues of Rett Patients and Healthy Individuals,” Plos Genetics 15(4):e1008043, Public Library of Science, United States (Apr. 2019… [cited by applicant]
Zhu, Y., et al., “The Achilles' Heel of Senescent Cells: From Transcriptome to Senolytic Drugs,” Aging Cell 14(4):644-658, Wiley-Blackwell, United Kingdom (Aug. 2015). [cited by applicant]
Li, W., et al., “Activation of Transposable Elements During Aging and Neuronal Decline in [cited by applicant]
Brydon, E., “CSHL neuroscientists show ‘jumping genes’ may contribute to aging-related brain defects,” CSHL Stories and Media, https://www.cshl.edu/cshl-neuroscientists-show-jumping-genes-may-contribute-to-aging-related… [cited by applicant]
Fikes, B. J., “HIV drugs may help Alzheimer's, say study proposing an undiscovered root cause,” The San Diego Union-Tribune (Nov. 23, 2018). [cited by applicant]
Achuthan, V., et al., “Physiological Mg [cited by applicant]
Alexandre, F., et al., “Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4′-Ethyny1-2-fluoro-2′-deoxyadenosine),” J. Med. Chem. 61… [cited by applicant]
Beutner, G., et al., “Follow the Silyl Cation: Insights into the Vorbrüggen Reaction,” Org. Process Res. Dev. 23(9):2050-2056, American Chemical Society, United States (Aug. 2019). [cited by applicant]
Boojamra, C., et al., “Design, synthesis, and anti-HIV activity of 4′-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors,” Bioorg. Med. Chem. 17(4):1739-1746, Elsevier, Netherlands (Feb. 2009). [cited by applicant]
Coufal, N., et al., “Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retrotransposition in human neural stem cells,” Proc. Natl. Acad. Sci. U.S.A. 108(51):20382-20387, National Academy of … [cited by applicant]
Cutinho, P., et al., “Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand-and structure-based approaches,” J. Biomol. Struct. Dyn. 38(6):… [cited by applicant]
Douville, R., et al., “Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis,” Ann. Neurol. 69(1):141-151, Wiley, United States (Jan. 2011). [cited by applicant]
Driver, C., and Vogrig, D., “Apparent retardation of aging in Drosophila melanogaster by inhibitors of reverse transcriptase,” Ann. N.Y. Acad. Sci. 717:189-197, Wiley-Blackwell, United States (Jun. 1994). [cited by applicant]
Fukuyama, K., et al., “Synthesis of EFdA via a diastereoselective aldol reaction of a protected 3-keto furanose,” Org. Lett. 17(4):828-831, American Chemical Society, United States (Feb. 2017). [cited by applicant]
Gallagher, W., et al., “A Claisen approach to 4′-Ed4T,” Org. Lett. 17(1):14-17, American Chemical Society, United States (Jan. 2015). [cited by applicant]
Gallagher, W., et al., “Selective opening of nucleoside derived acetals to form highly functionalized vinyl ethers,” Tetrahedron Lett. 61(15):151750, Elsevier, Netherlands (Feb. 2020). [cited by applicant]
Geser, F., et al., “Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases,” J. Neurol. 256(8):1205-1214, Springer Science+Business Media, Germany (Aug. 2009). [cited by applicant]
Haraguchi, K., et al., “Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine,” Bioorg. Med. Chem. Lett. 13(21):3775-3777, Elsevier, Netherlands (Nov. 2003). [cited by applicant]
Haraguchi, K., et al., “An alternative method suitable for a large scale synthesis of 4′-ethyny1-2′,3′-didehydro-3′-deoxythymidine,” Nucleic Acids Symp. Ser. (Oxf). 48:43-44, Oxford University Press, United Kingdom (200… [cited by applicant]
Haraguchi, K., et al., “Synthesis and anti-HIV activity of 4′-cyano-2′,3′-didehydro-3′-deoxythymidine,” Nucleotides Nucleic Acids 23(4):647-654, Taylor & Francis, United Kingdom (2004). [cited by applicant]
Haraguchi, K., et al., “A new approach to the synthesis of 4′-carbon-substituted nucleosides: development of a highly active anti-HIV agent 2′, 3′-didehydro-3′-deoxy-4′-ethynylthymidine,” Nucleotides Nucleic Acids 24(5-… [cited by applicant]
Haraguchi, K., et al., “Nucleophilic substitution at the 4′-position of nucleosides: new access to a promising anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine,” J. Org. Chem. 71(12):4433-4438, American Chemi… [cited by applicant]
Haraguchi, K., et al., “An alternative synthetic method for 4′-C-ethynylstavudine by means of nucleophilic substitution of 4′-benzoyloxythymine nucleoside,” Nucleotides Nucleic Acids 26(6-7):835-839, Taylor & Francis, U… [cited by applicant]
Haraguchi, K., et al., “From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4′-ethynylstavudine-Festinavir,” Curr. Pharm. Des. 19(10):1880-1897, Bentham Science Publishers, United Arab Emira… [cited by applicant]
Hattori, S., et al., “Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethyny1-2-fluoro-2′-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood… [cited by applicant]
Huffman, M., et al., “Design of an in vitro biocatalytic cascade for the manufacture of islatravir,” Science 368(6488)1255-1259, American Association for the Advancement of Science, United States (Apr. 2020). [cited by applicant]
Isono, Y., et al., “Synthesis of 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives with potential anti-HIV activity,” Antivir. Chem. Chemother. 22(2):57-65, International Medical Press, United Kingdom (Oct. 2011). [cited by applicant]
Jeong, B., et al., “The prevalence of human endogenous retroviruses in cerebrospinal fluids from patients with sporadic Creutzfeldt-Jakob disease,” J. Clin. Virol. 47(2):136-142, Elsevier, Netherlands (Feb. 2010). [cited by applicant]
Joshi, P., et al., “Inhibition of Heat Shock Protein 90 Prevents HIV Rebound,” J. Biol. Chem. 291(19):10332-10346, American Society for Biochemistry and Molecular Biology, United States (May 2016). [cited by applicant]
Kageyama, M., et al., “Concise synthesis of the anti-HIV nucleoside EFdA,” Biosci. Biotechnol. Biochem. 76(6):1219-1225, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Japan (Jun. 2012). [cited by applicant]
Kageyama, M., et al., “Enantioselective total synthesis of the potent anti-HIV nucleoside EFdA,” Org. Lett. 13(19)-5264-5266, American Chemical Society, United States (Oct. 2011). [cited by applicant]
Kamata, M., et al., “Synthesis of nucleotide analogues, EFdA, EdA and EdAP, and the effect of EdAP on hepatitis B virus replication,” Biosci. Biotechnol. Biochem. 84(2):217-227, Japan Society for Bioscience, Biotechnolo… [cited by applicant]
Kawamoto, A., et al., “2′-deoxy-4′-C-ethyny1-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants,” Int. J. Biochem. Cell Biol. 40(11):2410-2420, Elsevier, Netherlands (Apr. 2008). [cited by applicant]
Kirby, K., et al., “Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethyny1-2-fluoro-2′-deoxyadenosine,” Antimicrob. Agents Chemother. 57(12):6254-6264, American Society for Microbiology, Uni… [cited by applicant]
Kirby, K., et al., “The sugar ring conformation of 4′-ethyny1-2-fluoro-2′-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase,” Cell. Mol. Biol. 57(1):40-46, American Society fo… [cited by applicant]
Kovarova, M., et al., “HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection,” J. Antimicrob. Chemother. 71(11):3185-3194, Oxford Universit… [cited by applicant]
Kubota, Y., et al., “Synthesis and anti-HIV-1 evaluation of phosphonates which mimic the 5′-monophosphate of 4′-branched 2′,3′-didehydro-2′,3′-dideoxy nucleosides,” Bioorg. Med. Chem. 18(20):7186-7192, Elsevier, Netherl… [cited by applicant]
Kumamoto, H., et al., “Synthesis of carbocyclic analogues of 4′-ethyny1-and 4′-cyano-d4T,” Nucleic Acids Symp. Ser. (Oxf). (48):41-42, Oxford University Press, United Kingdom (2004). [cited by applicant]
Kumamoto, H., et al., “Synthesis of (+/−)-4′-ethynyl and 4′-cyano carbocyclic analogues of stavudine (d4T),” Nucleosides Nucleotides Nucleic Acids, 24(2):73-83, Taylor & Francis, United Kingdom (2005). [cited by applicant]
Kumamoto, H., et al., “Synthesis and anti-human immunodeficiency virus activity of 4′-branched (+/−)-4′-thiostavudines,” J. Med. Chem. 49(26):7861-7867, American Chemical Society, United States (Dec. 2006). [cited by applicant]
Kumamoto, H., et al., “Synthesis and antiviral evaluation of (+/−)-4′-ethynyl-5′-difluorocarbocyclic-d4T analogue,” Nucleic Acids Symp. Ser. (Oxf). (52):609-610, Oxford University Press, United Kingdom (2008). [cited by applicant]
Kumamoto, H., et al., “Synthesis of (±)-4′-ethyny1-5′,5′-difluoro-2′,3′-dehydro-3′-deoxy-carbocyclic thymidine: a difluoromethylidene analogue of promising anti-HIV agent Ed4T,” Tetrahedron Lett. 65(36):7630-7636, Elsev… [cited by applicant]
MacKenzie, I., and Rademakers, R., “The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia,” Curr. Opin. Neurol. 21(6):693-700, Lippincott Williams & Wilkins… [cited by applicant]
Maddaford, A., et al., “Stereoselective Synthesis of rac-4′-Ethyny1-2′-deoxy-and 4′-Ethynyl-2′,3′-dideoxy-2′,3′-didehydronucleoside Analogues,” Synthesis 9:1378-1384, Georg Thieme Verlag Stuttgart, Germany (2007). [cited by applicant]
Maidji, E., et al., “Cellular HIV Reservoirs and Viral Rebound from the Lymphoid Compartments of 4′-Ethyny1-2-Fluoro-2′-Deoxyadenosine (EFdA)-Suppressed Humanized Mice,” Viruses 11(3):256, MDPI, Switzerland (Mar. 2019). [cited by applicant]
Markowitz, M., et al., “Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3,” J. Infect. Dis. 221(9):1398-1406, Oxford University Press, United Kingdom (Apr. 2020). [cited by applicant]
Matsuzawa, T., et al., “EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium,” J. Invest. Dermatol. 134(4):1158-1161, Elsevier, Netherlands (Apr. 2014). [cited by applicant]
McLaughlin, M., et al., “Enantioselective Synthesis of 4′-Ethyny1-2-fluoro-2′-deoxyadenosine (EFdA) via Enzymatic Desymmetrization,” Org. Lett. 19(4):926-929, American Chemical Society, United States (Feb. 2017). [cited by applicant]
Michailidis, E., et al., “4′-Ethyny1-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms,” J. Biol. Chem. 289(35):24533-48, American Society for Biochemistry and Molecular Bio… [cited by applicant]
Michailidis, E., et al., “Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA,” Retrovirology 10:65, BioMed Central Ltd., United Kingdom (Jun. 2013). [cited by applicant]
Michailidis, E., et al., “Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-Ethyny1-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor,” J. Biol. Chem. 284(51)3… [cited by applicant]
Muftuoglu, Y., et al., “Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 40-ethyny1-2-fluoro-2′-deoxyadenosine (EFdA) using pre-steady-state kinetics,” Antiviral Res. 106:1-4, Elsev… [cited by applicant]
Muotri, A., et al., “L1 retrotransposition in neurons is modulated by MeCP2,” Nature 468(7322):443-446, Nature Publishing Group, United Kingdom (Nov. 2010). [cited by applicant]
Murphey-Corb, M., et al., “Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethyny1-2-fluoro-2′-deoxyadenosine in vitro and in vivo,” Antimicrob. Agents Chemother. 56(… [cited by applicant]
Nakata, H., et al., “Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethyny1-2-fluoro-2′-deoxyadenosine,” Antimicrob. Agents Chemother. 51(8):27… [cited by applicant]
Nawrat, C. C., et al., “Nine-Step Stereoselective Synthesis of Islatravir from Deoxyribose,” Org. Lett. 22(6):2167-2172, American Chemical Society, United States (Mar. 2020). [cited by applicant]
Ni, G., et al., “Review of α-nucleosides: from discovery, synthesis to properties and potential applications,” RSC Adv. 9(25):14302-14320, Royal Society of Chemistry, United Kingdom (May 2019). [cited by applicant]
Nomura, M., et al., “Nucleosides and nucleotides. 185. Synthesis and biological activities of 4′alpha-C-branched-chain sugar pyrimidine nucleosides,” J. Med. Chem. 42(15):2901-2908, American Chemical Society, United Sta… [cited by applicant]
Ohrui, H., et al., “2'-deoxy-4'-C-ethyny1-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in pl… [cited by applicant]
Ohrui, H., “Chapter 16: 4′-C-Ethyny1-2′-Deoxynucleosides,” in [cited by applicant]
Ohrui, H., “A Proposal of the Structure of Modified Nucleosides Expected to be Highly Anti-Viral Active and Lowly Toxic,” Nucleic Acids Symp. Ser. (Oxf) 52:631-632, Oxford University Press, United Kingdom (2008). [cited by applicant]
Ohrui, H., “Creation of Low Toxic Reverse-transcriptase Inhibitory Nucleosides that Prevent the Emergence of Drug-resistant HIV Variants,” J. Syn. Org. Chem. Jpn. 64(7):716-723, J- Stage, Japan (2006). [cited by applicant]
Ohrui, H., “Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants,” Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 87(3):53-65, Jap… [cited by applicant]
Oliveira, M., et al., “M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA,” J. Antimicrob. Chemother. 72(11):3008-3011, O… [cited by applicant]
O'Reilly, E., and Ryan, J., “Biocatalytic cascades go viral: An investigational drug targeting the HIV virus is synthesized with nine enzymes,” Biocatalysis 336(6470):1199-1200, American Association for the Advancement … [cited by applicant]
Ortiz, A., et al., “Scalable Synthesis of the Potent HIV Inhibitor BMS-986001 by Non-Enzymatic Dynamic Kinetic Asymmetric Transformation (DYKAT),” Angew. Chem. Int. Ed. Engl. 54(24):7185-7188, Wiley-VCH, Germany (Jun. 2… [cited by applicant]
Paintsil, E., et al., “Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine, a novel thymidine analog,” Antimicrob. Agents Chemother.… [cited by applicant]
Parang, K., et al., “Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E),” Molecules 25(10):2343, MDPI, Switzerland (May 2020). [cited by applicant]
Patel, N., et al., “Synthesis of Islatravir Enabled by a Catalytic, Enantioselective Alkynylation of a Ketone,” Org. Lett. 22(12):4659-4664, American Chemical Society, United States (Jun. 2020). [cited by applicant]
Rai, M., et al., “Emerging reverse transcriptase inhibitors for HIV-1 infection,” Expert Opin. Emerg. Drugs 23(2):149-157, Informa, United Kingdom (Jun. 2018). [cited by applicant]
Rana, A., et al., “Advances in Long-Acting Agents for the Treatment of HIV Infection,” Drugs 80(6):535-545, Springer Nature, Germany (Apr. 2020). [cited by applicant]
Salie, Z. L., et al., “Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethyny1-2-fluoro-2′-deoxyadenosine (EFdA),” Proc. Natl. Acad. Sci. U.S.A. 113(33):9274-9279, National Academy of Scien… [cited by applicant]
Sohl, C., et al., “Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4′-ethyny1-2-fluoro-2′-deoxyadenosine indicates a low potential for host toxi… [cited by applicant]
Takamatsu, Y., et al., “4′-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus,” Hepatology 62(4):1024-1036, Wiley, United States (Oct. 2015). [cited by applicant]
Takamatsu, Y., et al., “The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase,” Cell Chem. Biol. 25(10):1268-1278, Cell Press, United … [cited by applicant]
Takeuchi, T., et al., “Design, Synthesis, and Biological Evaluation of EdAP, a 4′-Ethynyl-2′-Deoxyadenosine 5′-Monophosphate Analog, as a Potent Influenza a Inhibitor,” Molecules 24(14):2603, MDPI, Switzerland (Jul. 201… [cited by applicant]
Tan, H., et al., “Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration,” Hum. Mol. Genet. 21(1):57-65, Oxford University Press, United Kingdom (Jan. 2012). [cited by applicant]
Tanaka, H., et al., “4′-Ethynylstavudine (4′-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants,” Antivir. Chem. Chemother. 16(4):217-221, Inter… [cited by applicant]
Tanaka, H., et al., “Synthetic use of epoxy-sugar nucleosides,” Nucleosides Nucleotides Nucleic Acids 26(6-7):547-554, Taylor & Francis, United Kingdom (2007). [cited by applicant]
Wu, V., et al., “MK-8591 (4′-Ethyny1-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture,” Antimicrob. Agents Chemother. 61(8):e00744-00717, American S… [cited by applicant]
Yang, G., et al., “Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4′-ethynylthymidine analog resistance profile,” Antimicrob. Agents Chemother. 53(11):4640-4646, A… [cited by applicant]
Yasutake, Y., et al., “Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine,” Sci. Rep. 10(1):3021, Nature Portfolio, Germany (Feb. 2020). [cited by applicant]
Zhang, W., et al., “Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor,” Int. J. Pharm. 461(1-2):203-213, Elsevier, Netherlands (Jan. 2014). [cited by applicant]
Zhang, W., et al., “In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers,” Eur. J. Pharmacol. 732:86-95, Elsevier, Netherlands (Jun. 2014… [cited by applicant]
Zhang, W., et al., “Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention,” Drug Dev. Ind. Pharm. 40(8):1101-1111, Marcel Dekker, United States (Aug. 2014). [cited by applicant]
Zhang, W., et al., “Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission,” Pharm. Res. 32(9):2960-2972, Springer Science+Business … [cited by applicant]
Asahchop, E., et al., “Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors,” Antimicrobial Agents and Chemotherapy 56(10):5000-5008, American Society for Microbiology, Un… [cited by applicant]
Kinney, J.W., et al., “Inflammation as a central mechanism in Alzheimer's disease,” Alzheimer's & Dementia: Translational Research & Clinical Interventions 4(1):575-590, Alzheimer's Association, United States (2018). [cited by applicant]
Akiyama, H., “Inflammation and Alzheimer's disease,” Neurobiology of Aging 21(3):383-421, Elsevier, The Netherlands (May-Jun. 2000). [cited by applicant]
Griffin, W.S.T., et al., “Inflammation and neurodegenerative diseases,” Am J Clin Nutr 83(suppl):470S-474S, American Society for Nutrition, United States (Feb. 2006). [cited by applicant]
Markowitz, M., et al., “EFdA (4′-ethyny1-2-fluoro-2′-deoxyadenosine, MK-8591): A Novel HIV-1 Reverse Transcriptase Translocation Inhibitor,” Curr Opin HIV AIDS 13(4):294-299, Wolters Kluwer Health, Inc., United States (… [cited by applicant]
Bollati, V., et al., “DNA methylation in repetitive elements and Alzheimer disease,” Brain Behav Immun 25(6):1078-1083, Elsevier, Netherlands (Aug. 2011). [cited by applicant]
Esposito, F., et al., “HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions,” Mol Biol Int 2012:586401, Hindawi… [cited by applicant]
Iijima, K., et al., “Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1,” Retrovirology 10:83, BioMed Central, United Kingdom (Aug. 2013). [cited by applicant]
Jones, R.B., et al., “Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition,” PLoS One 3(2):e1547, PLoS, United States (Feb. 2008). [cited by applicant]
Kharkevich, D.A., “Doses and Concentrations” in [cited by applicant]
Savage, A.L., et al., “Retrotransposons in the development and progression of amyotrophic lateral sclerosis,” J Neurol Neurosurg Psychiatry 90(3):284-293, BMJ, United Kingdom (Mar. 2019). [cited by applicant]
English language translation of Office Action for Russian Patent Application No. 2021119040/04(040073), received Aug. 3, 2023, 10 pages. [cited by applicant]
Meyzer, G., et al., “Reverse-Transcriptase Inhibitors in the Aicardi-Goutières Syndrome,” New England Journal of Medicine 379:2275-2277, Massachusetts Medical Society, United States (Dec. 2018). [cited by applicant]